Last reviewed · How we verify
CCX354-C
CCX354-C is a monoclonal antibody that targets the IL-1 receptor antagonist (IL-1RA) to prevent IL-1 mediated inflammation.
CCX354-C is a monoclonal antibody that targets the IL-1 receptor antagonist (IL-1RA) to prevent IL-1 mediated inflammation. Used for Treatment of Still's disease.
At a glance
| Generic name | CCX354-C |
|---|---|
| Sponsor | Amgen |
| Drug class | Monoclonal antibody |
| Target | IL-1RA |
| Modality | Small molecule |
| Therapeutic area | Inflammatory diseases |
| Phase | Phase 2 |
Mechanism of action
IL-1RA is a naturally occurring protein that inhibits the pro-inflammatory effects of IL-1. By targeting IL-1RA, CCX354-C aims to reduce inflammation and potentially treat various inflammatory diseases.
Approved indications
- Treatment of Still's disease
Common side effects
- Injection site reaction
- Headache
- Fatigue
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy (PHASE2)
- Study to Evaluate Safety and Efficacy of CCX 354-C in Subjects With Rheumatoid Arthritis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |